Analystreport
SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock.
Last scynexis, inc earnings: 11/13 09:05 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
| IMPACT SNAPSHOT | EVENT TIME: | SCYX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
SCYX alerts
SCYX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc news events
Weekly update
A roundup of the hottest topics
SCYX
NEWS
NEWS
- Scynexis And The Fungal Economy [Seeking Alpha][Seeking Alpha]
- SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development[PR Newswire]
- SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections[PR Newswire]
- SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp[PR Newswire]
- SCYNEXIS Inc (NASDAQ: SCYX) was given a new $6.00 price target on by analysts at LADENBURG THALM/SH SH. They now have a "buy" rating on the stock.[MarketBeat]
- More
SCYX
SEC Filings
SEC Filings
- 6/20/19 - Form 4
- 6/20/19 - Form 4
- 6/20/19 - Form 4
- SCYX's page on the SEC website
- More